Gastric motility in soluble guanylate cyclase alpha 1 knock-out mice.
The principal target of the relaxant neurotransmitter nitric oxide (NO) is soluble guanylate cyclase (sGC). As the alpha(1)beta(1)-isoform of sGC is the predominant one in the gastrointestinal tract, the aim of this study was to investigate the role of sGC in nitrergic regulation of gastric motility in male and female sGCalpha(1) knock-out (KO) mice. In circular gastric fundus muscle strips, functional responses and cGMP levels were determined in response to nitrergic and non-nitrergic stimuli. sGC subunit mRNA expression in fundus was measured by real-time RT-PCR; in vivo gastric emptying of a phenol red meal was determined. No changes were observed in sGC subunit mRNA levels between wild-type (WT) and KO tissues. Nitrergic relaxations induced by short trains of electrical field stimulation (EFS) were abolished, while those by long trains of EFS were reduced in KO strips; the latter responses were abolished by 1H[1,2,4,]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). The relaxations evoked by exogenous NO and the NO-independent sGC activator BAY 41-2272 were reduced in KO strips but still sensitive to ODQ. Relaxations induced by vasoactive intestinal peptide (VIP) and 8-bromo-cGMP were not influenced. Basal cGMP levels were decreased in KO strips but NO, long train EFS and BAY 41-2272 still induced a moderate ODQ-sensitive increase in cGMP levels. Gastric emptying, measured at 15 and 60 min, was increased at 15 min in male KO mice. sGCalpha(1)beta(1) plays an important role in gastric nitrergic relaxation in vitro, but some degree of nitrergic relaxation can occur via sGCalpha(2)beta(1) activation in sGCalpha(1) KO mice, which contributes to the moderate in vivo consequence on gastric emptying.
Vanneste
Gwen
G
Heymans Institute of Pharmacology, De Pintelaan 185, B-9000, Ghent, Belgium.
Dhaese
Ingeborg
I
Sips
Patrick
P
Buys
Emmanuel
E
Brouckaert
Peter
P
Lefebvre
Romain A
RA
D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D015237:Dinoprost / Q000494:pharmacology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D006162:Guanylate Cyclase / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009569:Nitric Oxide / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics* / Q000378:metabolism*; D000071756:Soluble Guanylyl Cyclase; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
C423582:3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine; D011720:Pyrazoles; D011725:Pyridines; D018160:Receptors, Cytoplasmic and Nuclear; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; D014660:Vasoactive Intestinal Peptide; D002217:Carbachol; D015237:Dinoprost; D006162:Guanylate Cyclase; D000071756:Soluble Guanylyl Cyclase; D006152:Cyclic GMP
Cell Signal. 2003 Feb;15(2):189-95
12464390
Cardiovasc Res. 2007 Oct 1;76(1):149-59
17610859
Dig Dis Sci. 2003 Oct;48(10):2064-8
14627356
J Biol Chem. 2004 Feb 13;279(7):5146-51
14610087
Gastroenterology. 2004 Mar;126(3):903-13
14988844
Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G988-92
15475488
Gastroenterology. 1978 Apr;74(4):722-5
204535
Gastroenterology. 1984 Jun;86(6):1592-610
6370777
Circ Res. 1990 Jun;66(6):1561-75
2160870
Eur J Pharmacol. 1990 Dec 4;191(3):303-9
1964906
Nature. 1991 Jun 6;351(6326):477-9
1675430
FEBS Lett. 1991 Nov 4;292(1-2):217-22
1683630
Br J Pharmacol. 1992 Mar;105(3):691-5
1352721
FEBS Lett. 1992 Jul 27;307(1):102-7
1353461
Br J Pharmacol. 1992 May;106(1):173-9
1504726
Eur J Biochem. 1992 Sep 1;208(2):467-73
1325910
Cell. 1993 Dec 31;75(7):1273-86
7505721
J Physiol. 1994 Apr 15;476(2):333-47
8046647
Eur J Pharmacol. 1994 Apr 21;256(2):125-9
7519557
Annu Rev Physiol. 1995;57:659-82
7539992
Eur J Pharmacol. 1995 Sep 25;284(3):265-70
8666008
Biochemistry. 1996 Jan 30;35(4):1093-9
8573563
Mol Pharmacol. 1996 Jul;50(1):1-5
8700100
Br J Pharmacol. 1996 Jun;118(3):695-703
8762096
Br J Pharmacol. 1996 Aug;118(7):1605-14
8842421
Can J Physiol Pharmacol. 1997 Jun;75(6):609-11
9276137
Naunyn Schmiedebergs Arch Pharmacol. 1997 Oct;356(4):488-94
9349636
Trends Pharmacol Sci. 1997 Dec;18(12):484-91
9458697
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1851-5
10677545
Br J Pharmacol. 2000 Jan;129(2):395-401
10694248
Br J Pharmacol. 2000 Apr;129(7):1315-22
10742286
Gastroenterology. 2000 Sep;119(3):766-73
10982771
Nat Cell Biol. 2001 Feb;3(2):193-7
11175752
J Biol Chem. 2001 Nov 30;276(48):44647-52
11572861
J Physiol. 2002 Jan 1;538(Pt 1):133-43
11773322
Nat Cell Biol. 2002 Apr;4(4):307-11
11887187
Biochem Biophys Res Commun. 2002 Apr 12;292(4):1057-62
11944922
Regul Pept. 2002 Oct 15;108(2-3):165-73
12220741
Dig Dis Sci. 1998 Mar;43(3):506-12
9539644
J Physiol. 1998 Jun 1;509 ( Pt 2):437-48
9575293
EMBO J. 1998 Jun 1;17(11):3045-51
9606187
Biochem J. 1998 Oct 1;335 ( Pt 1):125-30
9742221
Am J Physiol. 1998 Nov;275(5 Pt 1):G1173-8
9815048
Drug Discov Today. 2005 May 1;10(9):627-34
15894227
J Pharmacol Exp Ther. 2005 Jul;314(1):207-13
15792996
Exp Anim. 2005 Jul;54(4):309-17
16093644
Pharmacol Rev. 2005 Sep;57(3):315-38
16109838
J Pharmacol Exp Ther. 2006 Apr;317(1):258-66
16352702
J Clin Invest. 2006 Jun;116(6):1731-7
16614755
J Physiol. 2006 Nov 1;576(Pt 3):675-82
16973700
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7699-704
17452643
Curr Med Chem. 2003 Feb;10(4):291-301
12570702